Jazz's Ziihera wins FDA nod for frontline HER2+ gastric cancer, clearing use with chemo, with or without BeOne's Tevimbra.
Jazz Pharmaceuticals’ bispecific antibody Ziihera won a label expansion to treat certain patients with gastric cancer.
It’s the first time Ziihera will be marketed to …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Jazz Pharmaceuticals’ bispecific antibody Ziihera has gained FDA approval for first-line HER2-positive stomach cancer, unlocking…
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding…
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or…
FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops…
Bispecific antibody plus chemo with or without tislelizumab improves OS, PFS versus trastuzumab
